For a long time, “liver management” in small animal practice meant this:
- elevated ALT and ALP
- hepatoprotectant
- low protein food
- monitor
- repeat
Globally, that mindset is changing fast.
Referral centers and new guidelines are pushing us toward:
- earlier diagnosis
- biopsy based classification
- phenotype specific therapy
- aggressive management of nutrition and complications in both dogs and cats
This article summarizes the major treatment trends you should know so that your approach in daily practice stays aligned with where hepatology is actually going.
1. From “treat the ALT” to “treat the disease”
1.1 Classification before chronic medication
The ACVIM consensus on canine chronic hepatitis strongly emphasizes that chronic liver disease is not a single entity.
You are expected to ask:
- Is it inflammatory or immune mediated?
- Is there copper accumulation?
- Is it cholestatic or biliary?
- Is it vascular (portosystemic shunt)?
- Is it metabolic or vacuolar change?
- Is it neoplastic?
Biopsy, when safe, is still considered the gold standard, with copper quantification whenever chronic hepatitis is suspected.
For cats, more recent work in feline cholangitis reinforces subdivision into neutrophilic (acute or chronic) and lymphocytic forms, because treatment strategies are very different for these two groups.
1.2 Stable trend
Globally, the backbone remains:
- Abdominal ultrasound, including evaluation of gallbladder, bile ducts and portal vasculature
- Coagulation testing before biopsy where possible
- Ultrasound guided or surgical wedge biopsy in dogs
- Biopsy in cats when results will truly alter long term management
The key shift is philosophical: we do not commit dogs and cats to years of steroids or “liver supplements” without understanding the underlying phenotype whenever we can help it.
2. The four pillars of modern liver treatment
Across both species, current hepatology approaches fall into four repeating pillars.
2.1 Pillar 1: Remove or control the underlying cause
Immune mediated or idiopathic chronic hepatitis (dog)
Prednisone or prednisolone is still the first line in many dogs with idiopathic or immune mediated chronic hepatitis.
Cyclosporine has growing evidence as a steroid sparing or second line drug in presumed idiopathic chronic hepatitis, with retrospective studies showing enzyme improvement and long survival in many dogs.
Azathioprine or mycophenolate are still used in selected, closely monitored cases.
Copper associated hepatopathy (dog)
Trend is toward systematic recognition and treatment rather than incidental “we saw some copper”.
Current protocols favor:
- Low copper diets
- Chelation with D penicillamine or trientine when hepatic copper is clearly increased
- Long term monitoring of liver enzymes and, when feasible, repeat copper assessment
Biliary and gallbladder disease (dog and cat)
For gallbladder mucocele in dogs, recent data strongly support early cholecystectomy as the definitive treatment, with better survival when surgery is done before rupture and bile peritonitis.
For feline biliary tract disease, there is increased use of combined medical and surgical approaches in complex cases such as:
- obstructive cholangitis
- extrahepatic bile duct obstruction
- gallstones
Vascular anomalies (PSS)
For dogs and cats with congenital portosystemic shunts, the global standard remains:
- Medical stabilization using diet, lactulose and antibiotics
- Followed by surgical or interventional attenuation whenever possible because this is associated with better long term outcome than medical therapy alone
Infectious and toxic causes
- Leptospirosis in dogs: targeted antibiotic treatment plus vaccination in endemic regions
- Hepatotoxic drugs: rapid withdrawal, N acetylcysteine and supportive care where appropriate
2.2 Pillar 2: Support hepatocytes and bile flow
Ursodeoxycholic acid (UDCA)
UDCA remains one of the most widely used hepatobiliary drugs worldwide.
In dogs, it is commonly used for:
- cholestatic disease
- adjunct therapy in chronic hepatitis
- antilitogenic and choleretic support
In cats, recent MSD Vet Manual guidance is more selective.
UDCA is used in cats that have cholestasis but no evidence of destructive cholangitis.
It is no longer recommended in destructive cholangitis, due to evidence that it may aggravate small duct injury in destructive cholangiopathies.
Antioxidants and hepatoprotectants
Hepatoprotective agents such as:
- S adenosylmethionine (SAMe)
- Silybin or silymarin
- Vitamin E
are now part of most long term protocols for chronic hepatitis, copper associated hepatopathy and other chronic hepatopathies, even though the evidence base is still developing.
A 2025 review notes that these agents are widely used in practice to mitigate oxidative damage and fibrosis, despite limited large clinical trials in dogs.
2.3 Pillar 3: Nutritional and metabolic strategy
The nutrition message has changed significantly.
Chronic hepatitis (dog)
Modern guidance discourages reflexive late stage style protein restriction in all liver cases.
Instead, clinicians now:
- Maintain adequate high quality protein to preserve muscle mass
- Adjust copper content when copper disease is present
- Focus on total caloric intake and body condition
Hepatic encephalopathy (dog and cat)
Severe chronic protein restriction is now viewed as potentially harmful.
Recent work and earlier reviews emphasize:
- Lactulose
- Targeted antibiotics
- Moderate, good quality protein, sometimes with more plant and dairy sources
- Correction of precipitating factors like GI bleeding and constipation
Feline hepatic lipidosis
Globally, there is strong consensus that early, aggressive enteral feeding via feeding tube is the core of treatment.
Appetite stimulants, antiemetics and careful electrolyte correction are standard adjuncts.
Preventive focus is increasing:
- managing obesity
- reducing stress
- preventing anorexia during other illnesses
Obesity and metabolic liver change in pets
There is growing acceptance that obesity related fatty change in dogs and cats is clinically significant.
In human medicine, drugs such as GLP 1 agonists and other agents for metabolic steatohepatitis are transforming care, and veterinary hepatologists are watching this space closely, although these medications are not currently approved for animals.
2.4 Pillar 4: Early and aggressive management of complications
Survival is increasingly linked to how well we handle complications on top of primary therapy.
Hepatic encephalopathy
- Lactulose adjusted to produce soft, easily passed stools
- Non absorbable or systemic antibiotics based on current preference and resistance concerns
- Careful protein selection instead of starvation
- Avoidance of benzodiazepines and drugs that worsen mentation
Ascites and portal hypertension
- Sodium restriction
- Loop diuretics, sometimes combined with potassium sparing agents
- Attention to renal perfusion
- Use of colloids or plasma in selected cases, especially when coagulopathy and low albumin are present
Coagulopathy and bleeding risk
- Vitamin K for cholestatic disease
- Plasma transfusion before invasive procedures on a case by case basis
- Growing use of point of care tests such as thromboelastography in advanced centers
3. Dog specific: what is changing in canine liver treatment
3.1 Chronic hepatitis in dogs
Key clinical messages from the ACVIM consensus and newer follow up studies:
- Do not label “chronic hepatitis” without excluding other causes
- Rule out infectious, drug induced and purely reactive changes
- Biopsy with copper quantification whenever you suspect chronic hepatitis
Use immunosuppression strategically
- Prednisone or prednisolone remains first line in many idiopathic or immune mediated cases
- Cyclosporine is gaining ground as a useful option in dogs that require steroid sparing or in which steroids are contraindicated
Combine with hepatoprotectants and, where appropriate, UDCA
Many protocols now routinely layer:
- SAMe
- silybin
- sometimes UDCA
to address oxidative stress and cholestasis alongside immunosuppression.
Monitor more than ALT
Treatment success is assessed not only by ALT, but also:
- Albumin
- Cholesterol
- Bilirubin
- Coagulation
Newer outcome papers highlight that combination of histologic diagnosis and selected lab parameters can predict 2 year survival.
3.2 Gallbladder mucocele and biliary disease in dogs
Gallbladder mucoceles have become a major part of canine hepatobiliary practice.
Recent trends:
- Earlier cholecystectomy is favored in dogs with classic “kiwi” or stellate ultrasonographic pattern
- Elective or early surgery is associated with significantly better survival than delayed surgery after rupture and bile peritonitis
Newer studies on surgical technique and intraoperative support are improving perioperative survival, although short term mortality is still a concern, especially in septic bile peritonitis.
4. Cat specific: current treatment directions
4.1 Feline cholangitis and biliary disease
Recent reviews and the MSD Vet Manual summarize the present approach.
Neutrophilic cholangitis
Treated primarily as an infectious or ascending inflammatory disease.
Current trend:
- Broad spectrum antibiotics with good biliary penetration, guided by culture if possible
- Evaluation and management of concurrent pancreatitis and inflammatory bowel disease, because feline triaditis is common
Lymphocytic cholangitis
Treated as an immune mediated inflammatory disease.
- Prednisolone is the mainstay, often long term
- Chlorambucil may be used in refractory cases or where prednisolone sparing is needed
UDCA in cats: more selective use
UDCA can still be useful in non destructive cholangitis and primary intrahepatic cholestasis.
However, it is not recommended for destructive cholangitis patterns, due to concern for small duct injury.
4.2 Hepatic encephalopathy and portosystemic shunts in cats
Similar to dogs, cats with congenital shunts are managed medically with:
- diet
- lactulose
- antibiotics
before surgery.
A 2025 retrospective study in cats highlighted standardized lactulose based medical management protocols prior to any intervention in hepatic encephalopathy.
4.3 Feline hepatic lipidosis
Although not a “new trend,” what has changed is how aggressively clinicians are encouraged to act.
- Early feeding tube placement is now seen as the standard, not the last resort
- Balanced diets with adequate protein, carnitine and micronutrients are emphasized
- Appetite stimulants such as mirtazapine or capromorelin are widely incorporated in protocols to transition cats back to voluntary feeding
5. Emerging and future directions
A few areas are gaining attention and may shape how we treat liver disease in the near future.
Gut liver axis and microbiome
Work in dogs with portosystemic shunts and hepatic encephalopathy suggests that modulating the microbiome with diet, lactulose and probiotics can alter clinical signs and ammonia production.
More refined nutritional hepatology
Focus is shifting toward:
- amino acid patterns
- bile acid metabolism
- body composition
not just protein grams and fat percentage.
Translational insights from human metabolic steatohepatitis
New human drugs for metabolic steatohepatitis and obesity are reshaping how we think about fatty liver, bile acids and metabolic hormones.
There is strong interest in whether some of these concepts will eventually translate to veterinary therapeutics.
Advanced surgery and interventional radiology
Widening access to:
- CT angiography
- vessel sealing devices
- interventional radiology
is refining how complex biliary disease and intrahepatic shunts are managed, especially in referral centers.
6. Practical checklist for your next liver case
When a dog or cat comes in with elevated liver enzymes or suspected hepatobiliary disease, think along these lines:
Clarify the category
- Inflammatory
- copper related
- cholestatic or biliary
- vascular
- metabolic
- neoplastic
- secondary
Use imaging and, when safe, histopathology
- Ultrasound to define structure and identify surgical disease
- Biopsy and copper quantification when long term immunosuppression or chelation is considered
Match treatment to the phenotype
- Immune mediated: steroids plus or minus other immunosuppressants
- Copper associated: low copper diet plus chelators
- Biliary disease: early surgery or intervention when indicated, not endless “wait and see”
- Shunts: medical stabilization followed by attenuation where possible
- Lipidosis: feeding tube and full nutritional plan
Always remember the four pillars
- Remove or control cause
- Support hepatocytes and bile flow
- Optimize nutrition and metabolic health
- Control complications early and aggressively
Communicate prognosis and long term plan
Many dogs and cats with chronic liver disease can live for years with good quality of life if treated early and monitored properly.
Dr. Geoff Carullo is a Fellow and the current President of the Philippine College of Canine Practitioners.
Sharing this helps others understand what it really means to be a vet. If you found this valuable, like and follow for more insights.
